Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Colonic dysbiosis contributes to the development of colonic inflammation in ulcerative colitis (UC). Fecal microbial transplantation (FMT) is being proposed as a novel treatment for UC because it can eliminate dysbiosis; however, no prospective data exist. We initiated a pilot study to evaluate feasibility and safety of FMT in children with UC. METHODS: Ten children, 7 to 21 years of age, with mild-to-moderate UC (pediatric UC activity index [PUCAI] between 15 and 65) received freshly prepared fecal enemas daily for 5 days. Data on tolerability, adverse events, and disease activity were collected during FMT and weekly for 4 weeks after FMT. Clinical response was defined as decrease in PUCAI by >15, and decrease in PUCAI to <10 was considered clinical remission. RESULTS: No serious adverse events were noted. Mild (cramping, fullness, flatulence, bloating, diarrhea, and blood in stool) to moderate (fever) adverse events were self-limiting. One subject could not retain fecal enemas. Average tolerated enema volume by remaining 9 subjects was 165 mL/day. After FMT, 7 of the 9 (78%) subjects showed clinical response within 1 week, 6 of the 9 (67%) subjects maintained clinical response at 1 month, and 3 of the 9 (33%) subjects achieved clinical remission at 1 week after FMT. Median PUCAI significantly improved after FMT (P = 0.03) compared with the baseline. CONCLUSIONS: Fecal enemas were feasible and tolerated by children with UC. Adverse events were acceptable, self-limiting, and manageable by subjects. FMT indicated efficacy in the treatment of UC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These reports were followed by a number of small studies of FMT in children and adults with UC, CD, and pouchitis with mixed results.64–72”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [68]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 6×
“A recent study (7) evaluating the role of FMT in treating recurrent C difficile infection reported adverse events, which, similar to our study, were predominantly GI symptoms.”
BackgroundMethodResultInfluentialDysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713 · cited 1×
“The colonic microbiome in patients with UC has decreased richness and diversity (2,3) and is dysfunctional (4) (dysbiosis).”
BackgroundTurner, D., Otley, A. R., Mack, D., Hyams, J., de Bruijne, J., Uusoue, K., Walters, T. D., Zachos, M., Mamula, P., Beaton, D. E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.029 · Cited by 1,072 · cited 2×
“Therefore, clinical response was defined as a decrease in PUCAI by >15 points after FMT (17).”
BackgroundMethodTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 2×
“Donor exclusion criteria were guided by our IND, the American Association of Blood Bank Donor History Questionnaire version 1.1, and the recommendations from the American Gastroenterological Association (16).”
BackgroundInfluentialHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“Multiple studies have used various bowel sterilizing preparations (antibiotics and bowel cleanout) before FMT (19,20) to help donor microbiota establish in the new host.”
BackgroundKhoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 2×
“Recent evidence suggests that FMT, the infusion of fecal preparation from a healthy donor into the GI tract of a patient, is capable of altering the gut microbiome of the new host (6,7).”
BackgroundMethodGophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F., & Veldhuyzen van Zanten, S. J. O. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01004-06 · Cited by 550
Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases
Peterson, D. A., Frank, D. N., Pace, N. R., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.001 · Cited by 503 · cited 1×
“The colonic microbiome in patients with UC has decreased richness and diversity (2,3) and is dysfunctional (4) (dysbiosis).”
BackgroundTursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 1×
“Probiotics, for example, VSL#3, have shown some usefulness in the treatment of UC (5); however, not all probiotic formulations contain the same species, their efficacy may be strain specific, and understanding of their mechanism of action in the complex gastrointestinal (GI) microbiome is lacking.”
BackgroundTreatment of Ulcerative Colitis Using Fecal Bacteriotherapy
Borody, T. J., Warren, E. F., Leis, S., Surace, R., & Ashman, O. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200307000-00012 · Cited by 388 · cited 3×
“As reported previously (10), because of the chronic process of colonic inflammation, multiple FMT sessions may be needed to see a clinical response in UC.”
BackgroundMethod
Cited by
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Gut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
“difficile infection [32] and other GI conditions, although there is a growing interest in the use of several doses [35].”
BackgroundThe microbiome in early life: Implications for health outcomes
Tamburini, S., Shen, N., Wu, H. C., & Clemente, J. C. (2016) · Nature Medicine · doi:10.1038/nm.4142 · Cited by 1,213
The gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804
“%) within 1 week [59].”
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
“A phase 1 trial study conducted on pediatric UC patients reported that FMT was quite safe, with a high rate of clinical response (79%) within one week, and no serious side effects were observed [261].”
BackgroundFactors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Shen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Bian, X., Wu, W., Yang, L., Lv, L., Wang, Q., Li, Y., Ye, J., Fang, D., Wu, J., Jiang, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02259 · Cited by 530
“Four randomized controlled trials (RCTs) along with several cases have showed the efficacy of FMT to induce remission in active UC patients (Angelberger et al., 2013; Kump et al., 2013; Kunde et al., 2013; Cui et al., 2015; Moayyedi et al., 2015; Ren et al., 2015; Rossen et al., 2015; Suskind et al., 2015; Wei et al.,…”
BackgroundTurner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
“The largest pediatric series (9 children with UC) showed a 33% clinical remission (PUCAI < 10) with serial enemas (261).”
BackgroundColman, R. J., & Rubin, D. T. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.006 · Cited by 475
“…Frequency Donor Follow-up 1 Vermeire et al. (2012)27 4 CD Medically-refractory 200 g feces NJ infusion NR 3× in 36 h Healthy donor 2 months 2 Kunde et al. (2013)23 10 (−1 a) UC Mild–moderate 90–113 g/250 ml Enema up to (4 × 60ml)/day NR ×5 days Parents 6 weeks 3 Kump et al. (2013)22 6 UC…”
BackgroundIntestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease
Weingarden, A. R., & Vaughn, B. P. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1290757 · Cited by 463
“Further case series in children with UC demonstrated that FMT was safe and potentially effective in improving disease status.(102,103)”
BackgroundParamsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Regulation of life span by the gut microbiota in the short-lived African turquoise killifish
Smith, P., Willemsen, D., Popkes, M., Metge, F., Gandiwa, E., Reichard, M., & Valenzano, D. R. (2017) · eLife · doi:10.7554/elife.27014 · Cited by 423
“Manipulating the GM towards a healthy state has the therapeutic potential to improve health in specific diseases (Dodin and Katz, 2014; Kunde et al., 2013).”
BackgroundSystematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161174 · Cited by 409
“Borody, 2003 [67] Sore throat 3 8 Definitely Nasojejunal tube Lower gastrointestinal routes Kump, 2013 [68] Fever; Temporary increase of CRP and IL-6; Increase in stool frequency 1 6 Probably Colonoscopy Zhang, 2013 [69] Severe cold 1 1 Possibly Colonoscopy Quera, 2013 [44] Fever; Bacteremia 1 1 Probably Colonoscopy K…”
Hold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365
Why Is Initial Bacterial Colonization of the Intestine Important to Infants' and Children's Health?
Houghteling, P. D., & Walker, W. A. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000597 · Cited by 351
“Allan Walker, MD, Harvard Medical School, Massachusetts General Hospital, 114 16th St (114-3503), Charlestown, MA 02129-4404 (e-mail: wwalker@partners.”
BackgroundGut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Guo, X. Y., Liu, X. J., & Hao, J. Y. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12849 · Cited by 336
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
DuPont, A., Richards, Jelinek, K. A., Krill, J., Rahimi, E., & Ghouri, Y. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s27530 · Cited by 300
“More recently in 2013 Kunde et al 80 performed a single-center uncontrolled study of FMT in 10 children with UC, showing safety, tolerability, and clinical response.”
Cui, B., Feng, Q., Wang, H., Wang, M., Peng, Z., Li, P., Huang, G., Liu, Z., Wu, P., Fan, Z., et al. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12727 · Cited by 298
Manipulating the gut microbiota to maintain health and treat disease
Scott, K. P., Antoine, J.-M., Midtvedt, T., & van Hemert, S. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.25877 · Cited by 281
“Several studies with regard to ulcerative colitis have been performed, and in general remissions are obtained (98, 100, 101), even in children (102).”
BackgroundFecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions
Borody, T. J., Paramsothy, S., & Agrawal, G. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0337-1 · Cited by 275
Costello, S. P., Soo, W., Bryant, R. V., Jairath, V., Hart, A. L., & Andrews, J. M. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14173 · Cited by 258
Marcella, C., Cui, B., Kelly, C. R., Ianiro, G., Cammarota, G., & Zhang, F. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16148 · Cited by 250
The microbiota in inflammatory bowel disease
Sheehan, D., Moran, C., & Shanahan, F. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1064-1 · Cited by 246
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review
Rossen, N. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5359 · Cited by 242
Cui, H., Cai, Y., Wang, L., Jia, B., Li, J., Zhao, S., Chu, X., Lin, J., Zhang, X., Bian, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00571 · Cited by 240
Fecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Vindigni, S. M., Zisman, T. L., Suskind, D. L., & Damman, C. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644242 · Cited by 229
The microbiota in inflammatory bowel disease: Current and therapeutic insights
Lane, E. R., Zisman, T., & Suskind, D. (2017) · Journal of Inflammation Research · doi:10.2147/jir.s116088 · Cited by 226
Fuentes, S., Rossen, N. G., van der Spek, M. J., Hartman, J. H. A., Huuskonen, L., Korpela, K., Salojärvi, J., Aalvink, S., de Vos, W. M., D’Haens, G. R., et al. (2017) · The ISME Journal · doi:10.1038/ismej.2017.44 · Cited by 223
“FMT has been shown to have a role on colitis activity in several case series (Angelberger et al., 2012; Borody et al., 2012; Kump et al., 2013; Kunde et al., 2013; Aroniadis et al., 2016), as well as three randomized controlled trials (Moayyedi et al., 2015; Rossen et al., 2015; Paramsothy et al.,…”
MethodA role for bacterial urease in gut dysbiosis and Crohn’s disease
Ni, J., Shen, T.-C. D., Chen, E. Z., Bittinger, K., Bailey, A., Roggiani, M., Sirota-Madi, A., Friedman, E. S., Chau, L., Lin, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6888 · Cited by 218
Vandenplas, Y., Huys, G., & Daube, G. (2015) · Jornal de Pediatria · doi:10.1016/j.jped.2014.08.005 · Cited by 207
“However, results are often negative,(162) although positive results have been reported.(163) The transplanted microbiota should be carefully screened for pathogens.”
BackgroundIndoles from commensal bacteria extend healthspan
Sonowal, R., Swimm, A., Sahoo, A., Luo, L., Matsunaga, Y., Wu, Z., Bhingarde, J. A., Ejzak, E. A., Ranawade, A., Qadota, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706464114 · Cited by 197
“However, durable repopulation with the transplanted species requires an open niche within the intestinal tract, which may necessitate coordinate administration of antibiotics, and the procedure is less well tolerated in cases of severe colitis (55).”
BackgroundKump, P., Wurm, P., Gröchenig, H. P., Wenzl, H., Petritsch, W., Halwachs, B., Wagner, M., Stadlbauer, V., Eherer, A., Hoffmann, K. M., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14387 · Cited by 196
The equine intestinal microbiome
Costa, M., & Weese, J. S. (2012) · Animal Health Research Reviews · doi:10.1017/s1466252312000035 · Cited by 189
From Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Adverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 185
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases
Biazzo, M., & Deidda, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144119 · Cited by 185
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 180
“…Helicobacteraceae family and of enterohepatic Helicobacter spp. has been described in pediatric (Man et al., 2008; Kaakoush et al., 2010) and adult (Laharie et al., 2009) patients with CD, in adult patients with UC (Thomson et al., 2011), in mixed pediatric cohorts (Zhang et al., 2006), and in…”
BackgroundThe Fire Within: Microbes Inflame Tumors
Gagliani, N., Hu, B., Huber, S., Elinav, E., & Flavell, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.006 · Cited by 165
“However, the results of the first small studies are conflicting: whereas fecal transplantation was shown to be efficient in children and young adults with ulcerative colitis (Kunde et al., 2013), another study did not show efficacy in patients with chronic active ulcerative colitis (Kump et al.”
ResultQuera, R., Espinoza, R., Estay, C., & Rivera, D. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.10.002 · Cited by 156
Fecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O. G., Beaulieu, D. B., & Acra, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub2 · Cited by 164
“Some studies report relatively minor adverse eDects such as diarrhea, abdominal bloating, abdominal cramping, and fever in the immediate post-procedure period (Khoruts 2016; Kunde 2013).”
BackgroundInvolvement of Reduced Microbial Diversity in Inflammatory Bowel Disease
Gong, D., Gong, X., Wang, L., Yu, X., & Dong, Q. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6951091 · Cited by 142
Donor Recruitment for Fecal Microbiota Transplantation
Paramsothy, S., Borody, T. J., Lin, E., Finlayson, S., Walsh, A. J., Samuel, D., van den Bogaerde, J., Leong, R. W. L., Connor, S., Ng, W., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000405 · Cited by 149
Sood, A., Mahajan, R., Singh, A., Midha, V., Mehta, V., Narang, V., Singh, T., & Singh Pannu, A. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz060 · Cited by 149
Fecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O., Borromeo Beaulieu, D. M., & Acra, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774 · Cited by 158
Wang, Z.-K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14805 · Cited by 133
Cui, B., Li, P., Xu, L., Zhao, Y., Wang, H., Peng, Z., Xu, H., Xiang, J., He, Z., Zhang, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0646-2 · Cited by 148
“Early studies have suggested some therapeutic effect (of a single FMT) in the treatment of inflammatory bowel disease (IBD) including UC and Crohn’s disease (CD) [10–17].”
BackgroundLong-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Ding, X. L., Li, Q., Li, P., Zhang, T., Cui, B., Ji, G., Lü, X., & Zhang, F. (2019) · Drug Safety · doi:10.1007/s40264-019-00809-2 · Cited by 145
Goyal, A., Yeh, A., Bush, B. R., Firek, B. A., Siebold, L. M., Rogers, M. B., Kufen, A. D., & Morowitz, M. J. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx035 · Cited by 135
Fecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Pandit, N. G., Zaman, M., Minkoff, N. Z., Tanner‐Smith, E. E., Gomez-Duarte, O. G., Acra, S. A., & Nicholson, M. R. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub3 · Cited by 143
Davidovics, Z. H., Michail, S., Nicholson, M. R., Kociolek, L. K., Pai, N., Hansen, R., Schwerd, T., Maspons, A., Shamir, R., Szajewska, H., et al. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002205 · Cited by 126
“adult patients, including solid organ transplant recipients and patients with IBD (82,125,126).”
BackgroundFang, H., Fu, L., & Wang, J. (2018) · BioMed Research International · doi:10.1155/2018/8941340 · Cited by 123
Qazi, T., Amaratunga, T., Barnes, E. L., Fischer, M., Kassam, Z., & Allegretti, J. R. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1353848 · Cited by 137
Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis
Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., & Su, P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157259 · Cited by 116
“[36, 40] As for bowel lavage, polyethylene glycol was used in 52 patients of 5 studies.”
Basso, P. J., Câmara, N. O. S., & Sales‐Campos, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01571 · Cited by 136
“, 2017), IBD (Angelberger et al., 2013; Kunde et al., 2013) and metabolic syndrome (Vrieze et al.”
BackgroundRelationship between gut microbiota and development of T cell associated disease
Kosiewicz, M. M., Dryden, G. W., Chhabra, A., & Alard, P. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.019 · Cited by 117
Wu, R., Xiong, R., Li, Y., Chen, J., & Yan, R. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103062 · Cited by 126
Consensus report: faecal microbiota transfer – clinical applications and procedures
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P., Nieuwdorp, M., Norén, T., Ponsioen, C. Y., Rosien, U., Rossen, N. G., Satokari, R., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13868 · Cited by 114
Probiotic Use in Horses – What is the Evidence for Their Clinical Efficacy?
Schoster, A., Weese, J. S., & Guardabassi, L. (2014) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12451 · Cited by 117
“However, it has only recently received increased attention after several published studies showed that feces is a biologically active mixture of living organisms with great potential for treatment of C. difficile infection, 92, 93 and other gastrointestinal [94] [95] [96] and nongastrointestinal disorders.”
BackgroundCaldeira, L. D. F., Borba, H. H. L., Tonin, F. S., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238910 · Cited by 118
“When the fecal material was provided by relatives or acquaintances [18, 20, 23, 24, 26, 29, 30, 44], the pooled clinical response was 37.”
BackgroundTherapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches
Hansen, J. J., & Sartor, R. B. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-014-0042-7 · Cited by 104
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Hou, S., Yu, J., Li, Y., Zhao, D., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202413197 · Cited by 117
Therapeutic faecal microbiota transplantation: current status and future developments
Borody, T. J., Brandt, L. J., & Paramsothy, S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000027 · Cited by 114
Fecal Microbiota Transplantation for Inflammatory Bowel Disease.
Lopez, J., & Grinspan, A. M. (2016) · PubMed Central · Cited by 114
Li, M., Liang, P., Li, Z., Wang, Y., Zhang, G., Gao, H., Wen, S., & Tang, L. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00692 · Cited by 109
Fecal Microbiota Transplantation in Inflammatory Bowel Disease: Beyond the Excitement
Ianiro, G., Bibbò, S., Scaldaferri, F., Gasbarrini, A., & Cammarota, G. (2014) · Medicine · doi:10.1097/md.0000000000000097 · Cited by 98
“Most of these were case reports or case series, whereas 8 publications reported data from open-label trial with a small number of patients treated.(23,31,37,38,43,46,49,50) Really, from the study of Grehan et al,(23) only 1 patient had IBD of a total of 10 patients treated in a small open-label trial.”
BackgroundLeBlanc, A. D. M. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16518 · Cited by 101
Ihekweazu, F. D., Fofanova, T. Y., Queliza, K., Nagy-Szakal, D., Stewart, C. J., Engevik, M. A., Hulten, K. G., Tatevian, N., Graham, D. Y., Versalovic, J., et al. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1560753 · Cited by 100
Knoll, R. L., Forslund, S. K., Kultima, J. R., Meyer, C. U., Kullmer, U., Sunagawa, S., Bork, P., & Gehring, S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2016 · Cited by 103
Wei, Y., Zhu, W., Gong, J., Guo, D., Gu, L., Li, N., & Li, J. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/517597 · Cited by 91
Yao, W., Gong, J., Zhu, W., Tian, H., Ding, C., Gu, L., Li, N., & Li, J. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0869-2 · Cited by 102
“Exclusion criteria were as follows: (1) pregnancy or intention to become pregnant during the study period; (2) participation in any other clinical trials within the previous 3 months; (3) infectious colitis [6, 10]; (4) use of anti-TNF or methotrexate treatment within 8 weeks of inclusion; (5) use of antibiotics or pr…”
BackgroundLee, S. T. M., Kahn, S. A., Delmont, T. O., Shaiber, A., Esen, Ö. C., Hubert, N. A., Morrison, H. G., Antonopoulos, D. A., Rubin, D. T., & Eren, A. M. (2017) · Microbiome · doi:10.1186/s40168-017-0270-x · Cited by 102
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
Pandey, H., Jain, D., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Intestinal Research · doi:10.5217/ir.2023.00080 · Cited by 102
“Kunde et al. 386 found significant improvement in 9 children with UC who received FMT via enema.”
BackgroundLandy, J., Walker, A. W., Li, J. V., Al-Hassi, H. O., Ronde, E., English, N. R., Mann, E. R., Bernardo, D., McLaughlin, S. D., Parkhill, J., et al. (2015) · Scientific Reports · doi:10.1038/srep12955 · Cited by 92
He, Z., Li, P., Zhu, J., Cui, B., Xu, L., Xiang, J., Zhang, T., Long, C., Huang, G., Ji, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04984-z · Cited by 92
Gut microbiome interventions in human health and diseases
Nie, P., Li, Z., Wang, Y., Zhang, Y., Zhao, M., Luo, J., Du, S., Deng, Z., Chen, J., Wang, Y., et al. (2019) · Medicinal Research Reviews · doi:10.1002/med.21584 · Cited by 99
“Adverse reactions include diarrhea, cramping, belching, constipation, and aspiration pneumonia in CDI patients(237,242) and high fever in UC patients.(247) The U.”
BackgroundPopov, J., Caputi, V., Nandeesha, N., Rodriguez, D. A., & Pai, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111365 · Cited by 98
“…Inversely correlated with UC disease activity Beneficial effect of Coprococcus (butyrate-producing bacteria) to the colonic epithelium of UC patients Kunde et al. (2013) [143] Not applicable Suskind et al. (2015) [144] Not applicable RNA, ribonucleic acid; FMT, fecal microbiota transplant; dFMT,…”
BackgroundInfluentialKao, D., Hotte, N., Gillevet, P., & Madsen, K. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000131 · Cited by 87
Nusbaum, D. J., Sun, F., Ren, J., Zhu, Z., Ramsy, N., Pervolarakis, N., Kunde, S., England, W., Gao, B., Fiehn, O., et al. (2018) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiy133 · Cited by 88
“of 35 or less at baseline (Kunde et al. 2013) (Table S1, Supporting Information), suggesting that the FMT method used in this study may be less effective in patients with more severe disease.”
MethodSelf-citationFecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail
Pigneur, B., & Sokol, H. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.67 · Cited by 97
“Kunde et al.14 performed FMT in a small group of pediatric UC patients receiving enemas once a day for 5 days.”
MethodFecal Microbiota Transplantation in Inflammatory Bowel Disease
Boicean, A., Bîrluțiu, V., Ichim, C., Anderco, P., & Bîrsan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11041016 · Cited by 93
“2013 [57] 10 pediatric patients with mild-to-severe UC FMT with enemas for 5 days Patients achieved clinical remission at 1 week after FMT”
BackgroundFecal microbiota transplantation: facts and controversies
van Nood, E., Speelman, P., Nieuwdorp, M., & Keller, J. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000024 · Cited by 92
“A recent study of 10 children with ulcerative colitis treated with FMT showed 78% clinical response within 1 week; clinical remission in 33% of patients; and only mild and self-limiting adverse events [28].”
BackgroundOcansey, D. K. W., Wang, L., Wang, J., Yan, Y., Qian, H., Zhang, X., Xu, W., & Mao, F. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0251-8 · Cited by 92
Gargiullo, L., CHIERICO, F. D., D’Argenio, P., & Putignani, L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01704 · Cited by 89
“The currently published data show a clinical response rate ranging between 56 and 100% (Kunde et al., 2013; Wang A.Y. et al., 2016; Goyal et al., 2018).”
BackgroundLevy, A. N., & Allegretti, J. R. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819836893 · Cited by 83
Turner, D., Bishai, J. D., Reshef, L., Abitbol, G., Focht, G., Marcus, D., Ledder, O., Lev‐Tzion, R., Orlanski‐Meyer, E., Yerushalmi, B., et al. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz298 · Cited by 81
Bugging inflammation: role of the gut microbiota
Shen, S., & Wong, C. H. Y. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.12 · Cited by 82
The Microbiome and Sustainable Healthcare
Dietert, R. R., & Dietert, J. M. (2015) · Healthcare · doi:10.3390/healthcare3010100 · Cited by 82
“bloating, diarrhea and fever [202].”
Kelly, C. R., Kunde, S. S., & Khoruts, A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.060 · Cited by 79
Self-citationStep-up fecal microbiota transplantation (FMT) strategy
Cui, B., Li, P., Xu, L., Peng, Z., Xiang, J., He, Z., Zhang, T., Ji, G., Nie, Y., Wu, K., et al. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1151608 · Cited by 71
Damman, C. J., Brittnacher, M. J., Westerhoff, M., Hayden, H. S., Radey, M., Hager, K. R., Marquis, S. R., Miller, S. I., & Zisman, T. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133925 · Cited by 74
“[29] This paper had one of the greatest clinical responses to FMT of published prospective studies, but these results must be interpreted in the context of the mild to moderately affected pediatric population that was evaluated.”
ResultJalanka, J., Hillamaa, A., Satokari, R., Mattila, E., Anttila, V. ‐., & Arkkila, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14443 · Cited by 63
Pai, N., Popov, J., Hill, L., Hartung, E. E., Grzywacz, K., Moayyedi, P., Surette, M. G., Lee, C., Godin, D., Szamosi, J. C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.067 · Cited by 73
Vandenplas, Y., Huys, G. R. B., & Daube, G. (2015) · Jornal de Pediatria (Versão em Português) · doi:10.1016/j.jpedp.2014.08.006 · Cited by 73
Fecal microbiota transplant – a new frontier in inflammatory bowel disease
Sunkara, T., Rawla, P., Ofosu, A., & Gaduputi, V. V. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s176190 · Cited by 72
“59 Indeed, seven patients showed remission after 1 week and six of them up to 1 month.”
Metadata
- Authors
- Kunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S.
- Affiliations
- Spectrum Health (US)
- Michigan State University (US)
- Emory University (US)
- Corresponding author
- Kunde, Sachin
- Pham, Angela
- Crumb, Teri
- Duba, Meg
- Conrad, Harold
- Cloney, Deborah
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 2013-06
- Volume
- 56
- Issue
- 6
- Pages
- 597-601
- ISSN
- 0277-2116 (ISSN-L)
- 1536-4801
- OpenAlex
- W2121245825
- Cited by
- 314
- References
- 26
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 8 · 2023: 14 · 2022: 14 · 2021: 17 · 2020: 26 · 2019: 26 · 2018: 23 · 2017: 40 · 2016: 34 · 2015: 38 · 2014: 42 · 2013: 16
- FWCI
- 28.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pediatric Gastroenterology and Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Surgery › Anorectal Disease Treatments and Outcomes
- Keywords
- fecal microbiota transplantation, ulcerative colitis, pediatric inflammatory bowel disease, colonic dysbiosis, clinical remission, safety and tolerability, adverse events, disease activity
- MeSH terms
- Administration, Rectal, Adolescent, Adult, Biological Therapy, Child, Colitis, Ulcerative, Family, Feasibility Studies, Feces, Female, Follow-Up Studies, Hospitals, Pediatric, Humans, Male, Michigan, Outpatient Clinics, Hospital, Pilot Projects, Remission Induction, Severity of Illness Index, Therapies, Investigational, Donor Selection, Young Adult, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.